In brief
Indications
| Condition | From age | Requirement |
|---|---|---|
| Acquired hypothalamic obesity — after a tumour, surgery or injury of the hypothalamus | 4 | First approved targeted therapy for the condition; label expanded in 2026 |
| Bardet-Biedl syndrome | 2 | — |
| Obesity due to POMC, PCSK1 or LEPR deficiency | 2 | *Genetic confirmation mandatory* (pathogenic, likely pathogenic or variants of uncertain significance) |
All three groups share hyperphagia: not a habit of eating a lot, but insatiable hunger in which satiety never physiologically forms. That, rather than the number on the scale, usually defines the severity for patient and family.
Mechanism
The hypothalamus runs a chain that tells the brain energy is sufficient: leptin from adipose tissue → POMC neurons → production of α-melanocyte-stimulating hormone (α-MSH) → activation of MC4R → satiety and normal energy expenditure.
In POMC or PCSK1 deficiency the signalling peptide is never made; in LEPR deficiency leptin is not sensed; after hypothalamic damage the neurons serving the chain are destroyed. The result is identical: MC4R receives no signal, the brain concludes energy is short, and hunger switches on.
Setmelanotide is a synthetic α-MSH analogue. It activates the receptor directly, bypassing the broken link. Hunger falls, calorie intake drops and energy expenditure rises somewhat.
The mechanism carries a built-in consequence: the drug also weakly activates the related MC1R receptor, which governs skin pigmentation. Hence skin darkening — an expected effect rather than a complication.
Dosing and administration
▸subcutaneous, once daily, usually in the morning; ▸sites — abdomen, thigh or upper arm, rotated; ▸supplied as a 10 mg/mL solution in a multiple-dose vial; ▸the dose is titrated: start low, increase as tolerated.
| Indication and age | Starting dose | Maintenance |
|---|---|---|
| Hypothalamic obesity, from age 4 | 0.5 mg/day | up to 3 mg/day (weight-based under age 6) |
| Bardet-Biedl, POMC/PCSK1/LEPR — adults and from age 12 | 2 mg/day | up to 3 mg/day |
| Same indications, children 6–12 | 1 mg/day | as tolerated |
| Same indications, children 2–6 | 0.5 mg/day | as tolerated |
What the trials showed
▸Acquired hypothalamic obesity. In the phase 3 TRANSCEND trial published in the New England Journal of Medicine in 2026, BMI fell by roughly 15–16% over 52 weeks, with no reduction on placebo [1]. ▸Bardet-Biedl syndrome. A phase 3 trial confirmed weight reduction and reduced hyperphagia [2]. ▸POMC and LEPR deficiency. In phase 3 trials a substantial proportion of patients achieved clinically meaningful weight loss, with separately documented reductions in hunger [3].
Adverse effects
Common (20% or more in one or more groups):
▸skin and mole darkening — a consequence of MC1R activation; ▸injection-site reactions; ▸nausea, vomiting, diarrhoea, abdominal pain; ▸headache; ▸in men, spontaneous erections without sexual stimulation; in women, changes in arousal; ▸depression — requires active monitoring throughout treatment.
Requiring particular attention:
| Issue | Why it matters |
|---|---|
| Priapism — an erection lasting over 4 hours | A medical emergency requiring urgent care |
| Mood disturbance, suicidal thoughts | Mental-health monitoring is mandatory, particularly in adolescents |
| Allergic reactions | Standard vigilance for an injectable product |
| Benzyl alcohol in the formulation | Relevant in neonates and very young children |
What to understand before starting
▸This is treatment for a rare disease, not a weight-loss aid. The diagnosis must be confirmed: genetic testing where POMC, PCSK1 or LEPR deficiency is suspected, documented hypothalamic damage in the acquired form. ▸Therapy is long-term. Stopping returns the weight. ▸Skin will darken. Expected, reversible and not dangerous — but it is fairer to agree on it in advance. ▸Mood must be monitored. Depression sits among the common effects, and the patient population is largely children and adolescents. ▸It is prescription-only, prescribed and supervised by a clinician, and injections require training for the patient or parents.
Indications and eligibility can be discussed at a consultation; the product can be ordered here and is dispensed on prescription.
References
1. Miller JL, et al. Setmelanotide for the treatment of acquired hypothalamic obesity. N Engl J Med. 2026. PMID 42418774
2. Haqq AM, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(12):859–868. PMID 36356613
3. Clément K, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960–970. PMID 33137293
4. Argente J, et al. Setmelanotide in Bardet-Biedl syndrome: a 52-week comparison of phase 3 trial participants. Obesity (Silver Spring). 2026. PMID 41703984
5. IMCIVREE (setmelanotide) US Prescribing Information, Rhythm Pharmaceuticals.
Key facts
- Setmelanotide (brand name Imcivree, Rhythm Pharmaceuticals) is a synthetic analogue of α-melanocyte-stimulating hormone and a selective agonist of the melanocortin-4 receptor (MC4R). It does not "suppress appetite" in general terms — it restores signalling in one specific broken pathway.
- The indications are strictly limited: acquired hypothalamic obesity (from age 4), Bardet-Biedl syndrome (from age 2) and obesity due to genetically confirmed POMC, PCSK1 or LEPR deficiency (from age 2). Genetic testing is mandatory for the last group.
- It is not used in common obesity: if the MC4R pathway is intact, there is nothing to switch on. This is the fundamental difference from GLP-1 receptor agonists.
- Acquired hypothalamic obesity follows a tumour, surgery or injury involving the hypothalamus. Setmelanotide became the first approved targeted therapy for it, with the label expanded in 2026.
- The mechanism in one line: in POMC, PCSK1 or LEPR deficiency, or after hypothalamic damage, the MC4R receptor never receives the satiety signal, producing hyperphagia; the drug activates the receptor directly, bypassing the broken link.
- One adverse effect is built into the mechanism: setmelanotide weakly activates MC1R, the pigmentation receptor, so skin darkening occurs in most patients. It is expected rather than a complication.
- Administration is subcutaneous once daily, usually in the morning, into the abdomen, thigh or upper arm with site rotation. Supplied as a 10 mg/mL solution in a multiple-dose vial.
- Dosing is titrated and depends on indication and age: hypothalamic obesity starts at 0.5 mg/day rising to a maintenance 3 mg/day; in Bardet-Biedl syndrome and the genetic deficiencies, adults and adolescents start at 2 mg/day rising to 3 mg/day, children aged 6–12 start at 1 mg and children aged 2–6 at 0.5 mg.
- Efficacy: in acquired hypothalamic obesity a phase 3 trial showed a BMI reduction of roughly 15–16% over 52 weeks versus no reduction on placebo; in the genetic forms, substantial weight loss and — no less important — a reduction in hyperphagia.
- The effect lasts while treatment continues: after withdrawal weight generally returns. This is long-term therapy, not a course.
